Video

Increased Risk of Tardive Dyskinesia

Author(s):

John J. Miller, MD

How could drugs that block post-synaptic dopamine 2 receptors increase the risk for tardive dyskinesia over time?

John J. Miller, MD, talks about the increased risk of tardive dyskinesia on a synaptic level.

Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.

Related Videos
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
Related Content
phase 1
March 5th 2025

Phase 1 Study Initiated: NBI-1140675 for Neurological and Neuropsychiatric Conditions

Leah Kuntz
tardive versus spontaneous dyskinesia
April 17th 2019

Not All That Writhes Is Tardive Dyskinesia

Chris Aiken, MD
innovation
December 10th 2024

Psychopharmacology Innovations

John J. Miller, MD
tardive dyskinesia
September 24th 2024

Deutetrabenazine Shows Long Term Efficacy and Safety in Patients with Tardive Dyskinesia

Leah Kuntz
How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.
June 5th 2024

An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

Mehdi Farokhnia, MD, MPH
Rakesh Jain
June 3rd 2024

Why Clinicians Should Be Excited About Austedo XR

Leah Kuntz Rakesh Jain, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.